Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation

Liver Transplantation

Volumn 13, Issue 12, 2007, Pages 1637-1644

  Ito, Takashi ^a   Takada, Yasutsugu ^a   Ueda, Mikiko ^a   Haga, Hironori ^a   Maetani, Yoji ^a   Oike, Fumitaka ^a   Ogawa, Kohei ^a   Sakamoto, Seisuke ^a   Ogura, Yasuhiro ^a   Egawa, Hiroto ^a   Tanaka, Koichi ^a   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; DECARBOXYPROTHROMBIN; PROSTAGLANDIN E1; STEROID; TACROLIMUS; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER RESECTION; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PLASMAPHERESIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE RISK; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; PROTHROMBIN; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 37549068894     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21281     Document Type: Article

References (28)

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
2. Llovet J, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30: 1434-1440.
3. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001:33:1080-1086.
4. Todo S, Furukawa H, for the Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma. Experience in Japan. Ann Surg 2004;240:451-461.
5. Malago M, Sotiropoulos GC, Nadalin S, Valentin-Gamazo C, Paul A, Lang H, et al. Living donor liver transplantation for hepatocellular carcinoma: a single-center preliminary report. Liver Transpl 2006;12:934-940.
6. Herrero JI, Sangro B, Quiroga J, Pardo F, Herraiz M, Cienfuegos JA. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001;7:631-636.
7. Roayaie S, Frischer J, Emre H, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 cm. Ann Surg 2002;235:533-539.
8. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403.
9. Gondolesi GE, Roayaie S, Munoz L, Kim-Schluger L, Schiano T, Fishbein TM, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004;239: 142-149.
10. Kim SH, Choi D, Kim SH, Lim JH, Lee WJ, Kim MJ, et al. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol 2005;184:1069-1076.
11. Yao FY, Roberts JP. Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time? Liver Transpl 2004;10:919-921.
12. Majno, P, Mazzaferro V. Living donor liver transplantation for hepatocellular carcinoma for exceeding conventional criteria questions, answers and demands for common language. Liver Transpl 2006;12:896-898.
13. Takada Y, Ueda M, Ito T, Sakamoto S, Haga H, Maetani Y, et al. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 2006;12:912-919.
14. Inomata Y, Uemoto S, Asonuma K, Egawa H, Kiuchi T, Fujita S, et al. Right lobe graft in living donor liver transplantation. Transplantation 2000;69:258-264.
15. Kasahara M, Takada Y, Fujimoto Y, Ogura Y, Ogawa K, Uryuhara K, et al. Impact of right lobe with middle hepatic vein graft in right lobe living donor liver transplantation. Am J Transpl 2005;5:1339-1346.
16. Inomata Y, Tanaka K, Egawa H, Uemoto S, Ozaki N, Okajima H. The evolution of immunosuppression with FK506 in pediatric living related liver transplantation. Transplantation 1996;61:247-252.
17. Kozaki K, Egawa H, Ueda M, Oike F, Yoshizawa A, Fukatsu A, et al. The role of apheresis therapy for ABO incompatible living donor liver transplantation: the Kyoto University experience. Ther Apher Dial 2006;10:441-448.
18. Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, Cheb DS. Plasma desgamma-carboxy prothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990;11:481-488.
19. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Desgamma-carboxy prothrombin as a useful predisposing factor the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-569.
20. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086-1092.
21. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005;11: 1265-1272.
22. Grasso A, Stigliano R, Morisco F, Martines H, Quaglia A, Dhillon AP, et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation 2006; 81:1532-1541.
23. Sotiropoulos GC, Malago M, Molmenti E, Paul A, Nadalin S, Brokalaki E, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? Transplantation 2005;79:483-487.
24. Shah SA, Tan JCC, McGilvray ID, Cattral MS, Cleary SP, Levy GA, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006;81:1633-1639.
25. Kim YK, Kim CS, Chung GH, Han YM, Lee SY, Chon SB, et al. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. Am J Roentgenol 2006;186: 149-157.
26. Mao XG, Han X, Shan WD, Li AY. Multi-slice CT angiography by triple-phase enhancement in preoperative evaluation of hepatocellular carcinoma. Clin Med J 2005;118: 844-849.
27. Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004;239:150-159.
28. Otto G, Herber S, Heise M, Lohse AW, Monch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criteria for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006:12:1260-1267.